NLRP3 and COVID-19: The results obtained from this study can be applied in COVID-19 supportive therapy via the inhibition of the NLRP3 inflammasomes pathway by C. petasites and hesperetin that could result in the prevention of inflammatory responses upon the long-term inflammatory induction initiated by the spike glycoprotein of SARS-CoV-2.